The Academy of Managed Care Pharmacy (AMCP) thanks the Institute of Clinical and Economic Review (ICER) for the opportunity to provide comments on the “Potential Topics for Review in 2018” released on July 26, 2017. AMCP applauds ICER for considering new and emerging therapies, as well as incorporating public feedback, into the development of a robust review agenda for 2018.
The Academy of Managed Care Pharmacy (AMCP) thanks the International Society for Pharmacoeonomics and Outcomes Research (ISPOR) for the opportunity to comment on the Draft Special Task Force Report “A Health Economics Approach to US Value Assessment Frameworks” as updated on July 7, 2017.
The Academy of Managed Care Pharmacy thanks the Centers for Medicare and Medicaid Services (CMS) for the opportunity to comment on the Proposed Rule, Medicare Program; CY 2018 Updates to the Quality Payment Program (the Proposed Rule).
AMCP webinar that reviewed the FDA Reauthorization Act of 2017 (FDARA) which authorizes user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilars.
Press Release: Lowering the out-of-pocket costs of blood glucose testing strips can improve diabetes patients’ persistence with home monitoring, according to an article in the August 2017 issue of the Journal of Managed Care & Specialty Pharmacy (JMCP).
Conclusions reached in a recent New York Times article on outcomes-based contracting are premature, if not inaccurate, stated Academy of Managed Care Pharmacy (AMCP) CEO Susan A. Cantrell, RPh, CAE, adding, “It’s still the early innings for outcomes-based, or value-based, contracting for prescription drugs, and therefore, too soon to dismiss.”
AMCP supports a coalition of over 20 health care stakeholders committed to aligning 42 CFR Part 2 (Part 2) with HIPAA to allow appropriate access to patient information that is essential for providing whole-person care.
On behalf of the Academy of Managed Care Pharmacy (AMCP), I wanted to take this opportunity to express our strong support for the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (H.R. 2212), bipartisan legislation to increase competition and patient access to safe and affordable generic and biosimilar medicines.